|
12 Mar 2021 |
Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19
|
|
11 Mar 2021 |
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
|
|
11 Mar 2021 |
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
|
|
10 Mar 2021 |
Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
|
|
10 Mar 2021 |
Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.
|
|
10 Mar 2021 |
OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma
|
|
09 Mar 2021 |
Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
|
|
09 Mar 2021 |
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
|
|
09 Mar 2021 |
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
|
|
09 Mar 2021 |
GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer
|
|
09 Mar 2021 |
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
|
|
08 Mar 2021 |
Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
|
|
08 Mar 2021 |
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
|
|
07 Mar 2021 |
Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients
|
|
07 Mar 2021 |
Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
|
|
07 Mar 2021 |
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
|
|
05 Mar 2021 |
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
|
|
04 Mar 2021 |
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
|
|
03 Mar 2021 |
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
|
|
03 Mar 2021 |
Xentria Announces Submission of an Investigational New Drug (IND) Application for XTMAB-16 in the Treatment of Sarcoidosis
|
|
03 Mar 2021 |
Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates using T Cell Engager (TRACTr) Technology
|
|
03 Mar 2021 |
Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
|
|
03 Mar 2021 |
BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
|
|
02 Mar 2021 |
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
|
|
01 Mar 2021 |
IND Approval of Q-1802 from QureBio by FDA
|
